RVL Pharmaceuticals plc RVLP
0.03 +0.03
Day range unavailable
52-week range unavailable
- Market cap
- 3.14M
- Revenue (ttm)
- 36.92M
- Profit margin
- -184.91%
- Shares out
- 111.41M
- Forward P/E
- -0.09
- Beta
- 1.09
- Analysts
- Buy
- Price target
- 3.20 (+11247.5%)
- Earnings date
- Sep 30, 2024
No chart data for this range yet.
Key statistics
- Enterprise value
- 41.79M
- PEG ratio
- 0.00
- Price / sales
- 0.09
- Price / book
- 0.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -2.20%
- Free cash flow
- -25.56M
- Total cash
- 19.16M
- Total debt
- 58.15M
- Return on equity
- -182.44%
- Short % of float
- 4.54%
- 50-day average
- 0.085759
- 200-day average
- 0.65918
Analyst view
Consensus: buy
Buy
Price target (mean) 3.20 +11247.5% upside
Now 0.0282
- Target (low)
- 1.60
- Target (mean)
- 3.20
- Target (high)
- 6.00
Ratings (-1m) 3 3 buy · 0 hold · 0 sell
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Sep 30, 2024
Expected Sep 30, 2024. Consensus EPS estimate -0.08.
Financials — quick view
RVLP Revenue — quarterly 8.26M
RVLP Net income — quarterly -23.89M
RVLP EPS — quarterly -0.24
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 4, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Jan 4, 2024 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -0.13 | -0.13 | 0.00 | 0.00% |
| May 11, 2023 | Mar 1, 2023 | -0.12 | -0.12 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 30, 2023 | Barclays | main | — | Overweight |
| Mar 20, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Oct 24, 2022 | Barclays | main | — | Overweight |
| Dec 22, 2021 | HC Wainwright & Co. | init | — | Buy |
| Sep 23, 2021 | Cantor Fitzgerald | init | — | Overweight |
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- rvlpharma.com
News
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Thursday's Intraday Session 
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket 
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket - Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Your note
Sign in to keep a note on RVLP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTCHEM LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 19, 2023 | 6,123,340 |
| AVISTA HEALTHCARE PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 7, 2022 | 0 |
| BURGSTAHLER DAVID F | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 7, 2022 | 0 |
| COWAN GREGORY L | Director | Stock Award(Grant) | Jul 4, 2023 | 90,055 |
| DEBIASI MICHAEL J. | Director | Stock Award(Grant) | Jul 4, 2023 | 40,000 |
| HARSAUL FOUNDATION | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 19, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Athyrium Capital Management, LP | 13.11% | 14,600,444 | 8.18M | Jun 29, 2023 |
| Rovida Advisors Inc. | 2.69% | 3,000,000 | 1.68M | Jun 29, 2023 |
| ArrowMark Colorado Holdings LLC | 1.35% | 1,506,002 | 843.51K | Jun 29, 2023 |
| AIGH Capital Management LLC | 1.00% | 1,116,653 | 625.44K | Jun 29, 2023 |
| Morgan Stanley | 0.89% | 989,280 | 554.10K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 0.62% | 694,915 | 389.22K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Meridian Contrarian Fund | 1.35% | 1,506,002 | 843.51K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.20% | 224,896 | 125.96K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.12% | 134,224 | 112.75K | May 30, 2023 |
| iShares Micro Cap ETF | 0.10% | 108,862 | 12.19K | Aug 30, 2023 |
| Fidelity Total Market Index Fund | 0.06% | 63,268 | 53.15K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 45,207 | 37.97K | May 30, 2023 |